Reuters logo
BRIEF-Paion AG says Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial
June 28, 2017 / 6:44 PM / 3 months ago

BRIEF-Paion AG says Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial

June 28 (Reuters) - Paion Ag :

* Positive headline data in U.S. Phase III trial with Remimazolam for procedural sedation undergoing bronchoscopy

* Primary efficacy endpoint successfully achieved

* Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial in procedural sedation in patients undergoing bronchoscopy Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below